Economic evaluation of stereotactic radiotherapy and stereotactic radiosurgery technologies in the treatment of cancers: a systematic review
Authors:
- 20 May 2024
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Pharmacoeconomics & Outcomes Research
- Vol. 24 (8) , 899-922
Abstract
This systematic review study investigated the cost-effectiveness of stereotactic radiotherapy (SRT) and stereotactic radiosurgery (SRS) for treatment of various types of cancers. PubMed, Scopus, and Web of Science were searched from 30/12/1990 to 1/1/2023. The entered studies were screened in accordance with the inclusion criteria. The inclusion criteria encompassed all types of economic evaluation studies that investigated SRT/SRS technologies in the treatment of various cancers. A total of 47 articles were included in the review. The findings suggest that the use of Linear accelerator technology for the treatment of lung cancer (8 out of 12 studies) and prostate cancer (4 out of 5 studies) was a cost-effective strategy. Linear accelerator was found to be cost-effective in the treatment of liver metastases and liver cancer (2 out of 5 studies). All of the included studies that used Gamma Knife technology in brain metastases reported Gamma-Knife was a cost-effective treatment. Furthermore, in the treatment of prostate and liver cancer, proton therapy was identified as a cost-effective option than other treatments. This study confirms that SRT/SRS is a cost-effective procedure for the treatment of various types of cancers. Therefore, it is recommended to use SRT/SRS technology for optimal use of resources.Keywords
Funding Information
- Health Technology assessment office of ministry of Health and medical Education
This publication has 63 references indexed in Scilit:
- Better preservation of erectile function in localized prostate cancer patients with modern proton therapy: Is it cost‐effective?The Prostate, 2022
- Cost Effectiveness Analysis of Radiofrequency Ablation (RFA) Versus Stereotactic Body Radiotherapy (SBRT) for Early Stage Renal Cell Carcinoma (RCC)Clinical Genitourinary Cancer, 2022
- Cost-Effectiveness of Subsequent Whole-Brain Radiotherapy or Hippocampal-Avoidant Whole-Brain Radiotherapy Versus Stereotactic Radiosurgery or Surgery Alone for Treatment of Melanoma Brain MetastasesApplied Health Economics and Health Policy, 2020
- Cost‐effectiveness analysis of salvage therapies in locoregional previously irradiated head and neck cancerHead & Neck, 2018
- Cost-effectiveness of Gemcitabine Plus Modern Radiotherapy in Locally Advanced Pancreatic CancerClinical Therapeutics, 2016
- The cost-effectiveness of surgical resection and cesium-131 intraoperative brachytherapy versus surgical resection and stereotactic radiosurgery in the treatment of metastatic brain tumorsJournal of Neuro-Oncology, 2016
- Cost‐effectiveness analysis of neurocognitive‐sparing treatments for brain metastasesCancer, 2015
- Cost‐effectiveness of stereotactic body radiation therapy versus surgical resection for stage I non–small cell lung cancerCancer, 2013
- Comparing the cost-effectiveness of two brain metastasis treatment modalities from a payer's perspective: Stereotactic radiosurgery versus surgical resectionClinical Neurology and Neurosurgery, 2013
- Cost‐effectiveness of modern radiotherapy techniques in locally advanced pancreatic cancerCancer, 2011